Postischemic Administration of IL-1α Neutralizing Antibody Reduces Brain Damage and Neurological Deficit in Experimental Stroke

Circulation. 2020 Jul 14;142(2):187-189. doi: 10.1161/CIRCULATIONAHA.120.046301. Epub 2020 Jul 13.

Luca Liberale^{1

2}, Nicole R Bonetti^{1

3}, Yustina M Puspitasari¹, Lena Schwarz¹, Alexander Akhmedov¹, Fabrizio Montecucco^{4

5}, Frank Ruschitzka⁶, Jürg H Beer^{1

3}, Thomas F Lüscher⁷, John Simard⁸, Peter Libby⁹, Giovanni G Camici^{1

6

10}

¹ Center for Molecular Cardiology, University of Zürich, Schlieren, Switzerland (L.L, N.R.B., Y.M.P., L.S., A.A., J.H.B., T.F.L., G.G.C.).
² First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Italy (L.L.).
³ Department of Internal Medicine, Cantonal Hospital of Baden, Switzerland (N.R.B., J.H.B.).
⁴ IRCCS Ospedale Policlinico San Martino Genoa-Italian Cardiovascular Network, Italy (F.M.).
⁵ First Clinic of Internal Medicine, Department of Internal Medicine and Centre of Excellence for Biomedical Research (CEBR), University of Genoa, Italy (F.M.).
⁶ University Heart Center, Department of Cardiology, University Hospital Zurich, Switzerland (F.R., G.G.C.).
⁷ Royal Brompton and Harefield Hospitals and Imperial College, London, United Kingdom (T.F.L.).
⁸ XBiotech, Austin, TX (J.S.).
⁹ Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (P.L.).
¹⁰ Department of Research and Education, University Hospital Zurich, Switzerland (G.G.C.).

No abstract available

Keywords: blood brain barrier; cerebrovascular disease; inflammation; interleukin-1α; interleukins; neuroprotective agents; stroke.

Publication types